BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shimoji H, Karimata H, Nagahama M, Nishimaki T. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg 2013;37:2180-8. [PMID: 23649529 DOI: 10.1007/s00268-013-2074-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Sugimura K, Miyata H, Tanaka K, Makino T, Takeno A, Shiraishi O, Motoori M, Yamasaki M, Kimura Y, Hirao M, Fujitani K, Yasuda T, Mori M, Eguchi H, Yano M, Doki Y. Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients With Clinical T4b Esophageal Cancer: Short-term Results. Ann Surg 2021;274:e465-72. [PMID: 33065643 DOI: 10.1097/SLA.0000000000004564] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chiapponi C, Berlth F, Plum PS, Betzler C, Stippel DL, Popp F, Bruns CJ. Oligometastatic Disease in Upper Gastrointestinal Cancer - How to Proceed? Visc Med 2017;33:31-4. [PMID: 28612014 DOI: 10.1159/000455683] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
3 Effeney R, Shaw T, Burmeister BH, Burmeister E, Harvey J, Mai GT, Thomas J, Barbour AP, Smithers BM, Pryor DI. Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus. Clin Oncol (R Coll Radiol) 2018;30:642-9. [PMID: 30017206 DOI: 10.1016/j.clon.2018.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Huang TT, Li SH, Chen YH, Lu HI, Lo CM, Fang FM, Chou SY, Chiu YC, Chou YP, Wang YM. Definitive chemoradiotherapy for clinical T4b esophageal cancer - Treatment outcomes, failure patterns, and prognostic factors. Radiother Oncol 2021;157:56-62. [PMID: 33482233 DOI: 10.1016/j.radonc.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 van Rossum PSN, Mohammad NH, Vleggaar FP, van Hillegersberg R. Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nat Rev Gastroenterol Hepatol. 2018;15:235-249. [PMID: 29235549 DOI: 10.1038/nrgastro.2017.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
6 Taniyama TK, Tsuda T, Miyakawa K, Arai H, Doi A, Hirakawa M, Horie Y, Mizukami T, Izawa N, Ogura T, Sunakawa Y, Nakajima TE. Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy. Esophagus 2020;17:67-73. [PMID: 31506805 DOI: 10.1007/s10388-019-00691-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Reeh M, Metze J, Uzunoglu FG, Nentwich M, Ghadban T, Wellner U, Bockhorn M, Kluge S, Izbicki JR, Vashist YK. The PER (Preoperative Esophagectomy Risk) Score: A Simple Risk Score to Predict Short-Term and Long-Term Outcome in Patients with Surgically Treated Esophageal Cancer. Medicine (Baltimore) 2016;95:e2724. [PMID: 26886613 DOI: 10.1097/MD.0000000000002724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Mori M, Doki Y. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann Gastroenterol Surg. 2019;3:169-180. [PMID: 30923786 DOI: 10.1002/ags3.12222] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lee CC, Soon YY, Vellayappan B, Ho F, Tey JCS. Survival rates and safety associated with chemoradiotherapy followed by surgery and chemoradiotherapy alone for patients with T4 esophageal cancer: a systematic review and meta-analysis. Acta Oncol 2022;:1-11. [PMID: 35450511 DOI: 10.1080/0284186X.2022.2062680] [Reference Citation Analysis]
10 Ishikawa K, Nakamatsu K, Shiraishi O, Yasuda T, Nishimura Y. Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer. Int J Clin Oncol 2015;20:531-7. [PMID: 25073955 DOI: 10.1007/s10147-014-0736-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
11 Yamaguchi S, Morita M, Yamamoto M, Egashira A, Kawano H, Kinjo N, Tsujita E, Minami K, Ikebe M, Ikeda Y, Kunitake N, Toh Y. Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion. Ann Surg Oncol 2018;25:3280-7. [PMID: 30051363 DOI: 10.1245/s10434-018-6656-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Takeuchi M, Kawakubo H, Mayanagi S, Yoshida K, Irino T, Fukuda K, Nakamura R, Wada N, Takeuchi H, Kitagawa Y. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma. World J Surg. 2019;43:2006-2015. [PMID: 30972432 DOI: 10.1007/s00268-019-05000-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
13 Raman V, Jawitz OK, Voigt SL, Farrow NE, Yang CJ, D'Amico TA, Harpole DH Jr. Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis. Ann Thorac Surg 2019;108:1633-9. [PMID: 31356800 DOI: 10.1016/j.athoracsur.2019.05.091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Defize IL, van der Horst S, Bülbul M, Haj Mohammad N, Mook S, Meijer GJ, Brosens LAA, Ruurda JP, van Hillegersberg R. Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy. Ann Surg Oncol 2021;28:2730-8. [PMID: 33341917 DOI: 10.1245/s10434-020-09425-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yin S, Chao Y, Tseng C, Chang H, Liu Y, Wu Y, Chen T, Yeh C. Bronchoscopic finding determined outcome after chemoradiotherapy in esophageal cancer patients with airway invasion: T4b-Airway Esophageal Cancer. J Surg Oncol 2014;109:808-11. [DOI: 10.1002/jso.23578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Tian D, Zhang L, Wang Y, Chen L, Zhang K, Zhou Y, Wen H, Fu M. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes. Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Makino T, Yamasaki M, Tanaka K, Tatsumi M, Takiguchi S, Hatazawa J, Mori M, Doki Y. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery 2017;162:836-45. [PMID: 28711321 DOI: 10.1016/j.surg.2017.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
18 Akutsu Y, Kono T, Uesato M, Hoshino I, Murakami K, Aoyagi T, Ota T, Toyozumi T, Suito H, Kobayashi H, Harada R, Uno T, Matsubara H. Is the outcome of a salvage surgery for T4 thoracic esophageal squamous cell carcinoma really poor? World J Surg 2014;38:2891-7. [PMID: 24952078 DOI: 10.1007/s00268-014-2668-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
19 Goense L, van Rossum PS, Kandioler D, Ruurda JP, Goh KL, Luyer MD, Krasna MJ, van Hillegersberg R. Stage-directed individualized therapy in esophageal cancer. Ann N Y Acad Sci 2016;1381:50-65. [PMID: 27384385 DOI: 10.1111/nyas.13113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
20 Karimata H, Shimoji H, Nishimaki T. Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy. Surg Today 2015;45:479-86. [PMID: 25059344 DOI: 10.1007/s00595-014-0980-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
21 Makino T, Yamasaki M, Miyazaki Y, Wada N, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Dis Esophagus 2018;31. [PMID: 29190316 DOI: 10.1093/dote/dox130] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
22 Toxopeus EL, Talman S, van der Gaast A, Spaander VM, van Rij CM, Krak NC, Biermann K, Tilanus HW, Mathijssen RH, van Lanschot JJ, Wijnhoven BP. Induction chemotherapy followed by surgery for advanced oesophageal cancer. Eur J Surg Oncol 2015;41:323-32. [PMID: 25534280 DOI: 10.1016/j.ejso.2014.11.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Grimminger PP, der Horst S, Ruurda JP, Det M, Morel P, Hillegersberg R. Surgical robotics for esophageal cancer. Ann N Y Acad Sci 2018;1434:21-6. [DOI: 10.1111/nyas.13676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Akutsu Y, Matsubara H. Chemoradiotherapy and surgery for T4 esophageal cancer in Japan. Surg Today. 2015;45:1360-1365. [PMID: 25583206 DOI: 10.1007/s00595-015-1116-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
25 Anderegg MCJ, Ruurda JP, Gisbertz SS, Blom RLGM, Sosef MN, Wijnhoven BPL, Hulshof MCCM, Bergman JJGHM, van Laarhoven HWM, van Berge Henegouwen MI. Feasibility of extended chemoradiotherapy plus surgery for patients with cT4b esophageal carcinoma. Eur J Surg Oncol 2020;46:626-31. [PMID: 31706717 DOI: 10.1016/j.ejso.2019.10.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sugimura K, Miyata H, Yano M, Yanagimoto Y, Ho MJ, Kobayashi S, Takahashi H, Omori T, Ohue M, Sakon M. Is 18F-FDG-PET useful for predicting R0 resection after induction therapy for initially unresectable locally advanced esophageal carcinoma? Gen Thorac Cardiovasc Surg 2017;65:455-62. [PMID: 28585161 DOI: 10.1007/s11748-017-0786-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]